David Dix

Clinical Professor

The University of British Columbia

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Cancer Biology Cancer Biology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Dix is a Clinical Professor at the University of British Columbia, Canada. His research focuses on pediatric oncology, particularly in symptom screening and treatment outcomes for children with cancer. He has authored several recent articles exploring issues such as lymph node involvement in Wilms tumor and the development of tools for assessing quality of life in pediatric patients. Dr. Dix's work contributes significantly to precision oncology initiatives and the improvement of clinical care in pediatric cancer treatment.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (20)

Daniel Benedetti

Vanderbilt University Medical Center

UNITED STATES

David Dix

Research Interests

Explore related searches

Contact this professor

About

Articles (21)

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Symptom Screening for Hospitalized Pediatric Patients with Cancer: A Randomized Clinical Trial

Total colonic supply via the inferior mesenteric artery

Establishing Reliability and Validity of the FACE-Q Craniofacial Module for Pediatric Head and Neck Cancer

Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532

Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children's Oncology Group Study, AREN03B2

Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5

Validation of co-Symptom Screening in Pediatrics Tool: A novel dyadic approach to symptom screening in pediatric patients receiving cancer treatment

Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors

Reductions in Bone Mineral Density Are Apparent Early in Children With Prevalent Osteonecrosis Lesions Following Leukemia Therapy

Vertebral Body Reshaping after Fractures: An Important Index of Recovery in Glucocorticoid-Treated Children

The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor

Circulating Tumor DNA as a Biomarker in Patients with Stage III and IV Wilms Tumor: Analysis from a Children's Oncology Group Trial, AREN0533

Complete resolution of alopecia totalis following chemotherapy for B-cell acute lymphoblastic leukemia

High urinary CXCL10/Cr with onset of Burkitt lymphoma in a pediatric kidney transplant recipient

Nonoperative Management of Childhood Calvarial Langerhans-Cell Histiocytosis

Reply to the Letter to the Editor by Daniel M. Green

Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury

Impact of the first generation of children⇔s oncology group clinical trials on clinical practice for wilms tumor

The Accuracy of Incident Vertebral Fracture Detection in Children Using Targeted Case-Finding Approaches

Association between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients receiving intravenous etoposide.

Collaborators (20)

Daniel Benedetti

Conrad Fernandez

Stephanie Atkinson

Mitchell Elliott

Anna Lee

Liny John

Pedro Farinha

Paul Steinbok

Jennifer Chan

lucia nappi

Harold "Bo" Lovvorn, III

Kristin Houghton

Leanne M Ward

Joon Seon Lee

Manfred Gessler

David Gisselsson

George Tomlinson

Charlene Rae

James I. Geller

Darrell Underhill

Make your next move.